BRYAN ERIC STRAUSS

(Fonte: Lattes)
Índice h a partir de 2011
17
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/05 - Laboratório de Poluição Atmosférica Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2022 ×

Resultados de Busca

Agora exibindo 1 - 7 de 7
  • bookPart
    Terapias alvo dirigidas, gênicas e oncolíticas
    (2022) RODRIGUES, Otavio Augusto; STRAUSS, Bryan Eric
  • conferenceObject
  • article 2 Citação(ões) na Scopus
    Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy
    (2022) V, Ruan F. Medrano; SALLES, Thiago A.; DARIOLLI, Rafael; ANTUNES, Fernanda; FEITOSA, Valker A.; HUNGER, Aline; CATANI, Joao P. P.; MENDONCA, Samir A.; TAMURA, Rodrigo E.; LANA, Marlous G.; RODRIGUES, Elaine G.; STRAUSS, Bryan E.
    Balancing safety and efficacy is a major consideration for cancer treatments, especially when combining cancer immunotherapy with other treatment modalities such as chemotherapy. Approaches that induce immunogenic cell death (ICD) are expected to eliminate cancer cells by direct cell killing as well as activation of an antitumor immune response. We have developed a gene therapy approach based on p19Arf and interferon-beta gene transfer that, similar to conventional inducers of ICD, results in the release of DAMPS and immune activation. Here, aiming to potentiate this response, we explore whether association between our approach and treatment with doxorubicin (Dox), a known inducer of ICD, could further potentiate treatment efficacy without inducing cardiotoxicity, a critical side effect of Dox. Using central composite rotational design analysis, we show that cooperation between gene transfer and chemotherapy killed MCA205 and B16F10 cells and permitted the application of reduced viral and drug doses. The treatments also cooperated to induce elevated levels of ICD markers in MCA205, which correlated with improved efficacy of immunotherapy in vivo. Treatment of subcutaneous MCA205 tumors associating gene transfer and low dose (10 mg/kg) chemotherapy resulted in inhibition of tumor progression. Moreover, the reduced dose did not cause cardiotoxicity as compared to the therapeutic dose of Dox (20 mg/kg). The association of p19Arf/interferon-beta gene transfer and Dox chemotherapy potentiated antitumor response and minimized cardiotoxicity.
  • article 2 Citação(ões) na Scopus
    Reporter system controlled by the involucrin promoter as a tool to follow epidermal differentiation
    (2022) FERNANDES, Myrian Thiago Pruschinski; SANTOS, Jeniffer Farias dos; FREITAS, Bruna Leticia; REIGADO, Gustavo Roncoli; ANTUNES, Fernanda; TESSAROLLO, Nayara Gusmao; CHAMBERGO, Felipe Santiago; STRAUSS, Bryan Eric; NUNES, Viviane Abreu
    Various approaches have been explored to study skin biology, including the use of stem cells. Mesen-chymal stem cells (MSCs) from the umbilical cord can be safely and easily obtained; however, a simple strategy to monitor their differentiation is essential. Involucrin is a marker of keratinocyte differentiation, and its promoter (pINV) directs stratum-specific expression of this protein. We designed a reporter system containing EGFP under the control of pINV to assess MSC transdifferentiation into keratinocytes. The functional sequence of pINV was inserted into a lentiviral vector, producing LeGO-GpINV. MSCs were transduced with LeGO-GpINV and induced to transdifferentiate into keratinocytes under cultivation with keratinocyte serum-free medium. MSC transdifferentiation was confirmed by morphological changes and by the expression of epidermal markers by flow cytometry, quantitative PCR, Western blot and the activity of epidermal kallikreins 5, 6 and 7. After 14 days of transdifferentiation, MSCs transduced with LeGO-GpINV showed an increase in EGFP fluorescence and expressed CK10, CK14, involucrin and filag-grin. There was also an increase in kallikrein activity. This reporter system allowed us to temporally assess epidermal differentiation, simultaneously with involucrin expression, opening possibilities for the in vivo study of skin biology and in regenerative medicine.(c) 2022 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
  • conferenceObject
  • article 3 Citação(ões) na Scopus
    Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma
    (2022) CERQUEIRA, Otto Luiz Dutra; ANTUNES, Fernanda; ASSIS, Nadine G.; CARDOSO, Elaine C.; CLAVIJO-SALOMON, Maria A.; DOMINGUES, Ana C.; TESSAROLLO, Nayara G.; STRAUSS, Bryan E.
    Melanoma is the deadliest type of skin cancer with steadily increasing incidence worldwide during the last few decades. In addition to its tumor associated antigens (TAAs), melanoma has a high mutation rate compared to other tumors, which promotes the appearance of tumor specific antigens (TSAs) as well as increased lymphocytic infiltration, inviting the use of therapeutic tools that evoke new or restore pre-existing immune responses. Innovative therapeutic proposals, such as immune checkpoint inhibitors (ICIs), have emerged as effective options for melanoma. However, a significant portion of these patients relapse and become refractory to treatment. Likewise, strategies using viral vectors, replicative or not, have garnered confidence and approval by different regulatory agencies around the world. It is possible that further success of immune therapies against melanoma will come from synergistic combinations of different approaches. In this review we outline molecular features inherent to melanoma and how this supports the use of viral oncolysis and immunotherapies when used as monotherapies or in combination.
  • conferenceObject